About Schizophrenia Therapeutics Schizophrenia is a chronic mental disorder that alters the perception, thinking, and social behavior of an individual. Individuals suffering from this disease face difficulty in distinguishing between imaginary things and reality. Although schizophrenia is not as prevalent as other mental disorders, it affects 7 or 8 individuals out of 1,000 people. Globally, the disease affects 1% of the total population. Schizophrenic patients are usually diagnosed with low levels of dopamine and serotonin. These are major neurotransmitters in the brain and are responsible for transmitting nerve signals from one neuron to another neuron. Deficiency of these neurons in the brain leads to impairment of thinking, perception, and the activity of an individual. At present, the treatment regimen for this disease focuses on relieving symptoms. Thus, antipsychotic drugs are used as a standard treatment regimen for schizophrenia. It helps in reversing the low levels of dopamine and serotonin, thereby improving the patient's condition. Technavio’s analysts forecast the global schizophrenia therapeutics market to grow at a CAGR of 1.84% during the... Research Beam Model: Research Beam Product ID: 1791984 3500 USD New
Global Schizophrenia Therapeutics Market 2017-2021
 
 

Global Schizophrenia Therapeutics Market 2017-2021

  • Category : Healthcare
  • Published On : July   2017
  • Pages : 81
  • Publisher : Technavio
 
 
 
About Schizophrenia Therapeutics
Schizophrenia is a chronic mental disorder that alters the perception, thinking, and social behavior of an individual. Individuals suffering from this disease face difficulty in distinguishing between imaginary things and reality. Although schizophrenia is not as prevalent as other mental disorders, it affects 7 or 8 individuals out of 1,000 people. Globally, the disease affects 1% of the total population. Schizophrenic patients are usually diagnosed with low levels of dopamine and serotonin. These are major neurotransmitters in the brain and are responsible for transmitting nerve signals from one neuron to another neuron. Deficiency of these neurons in the brain leads to impairment of thinking, perception, and the activity of an individual. At present, the treatment regimen for this disease focuses on relieving symptoms. Thus, antipsychotic drugs are used as a standard treatment regimen for schizophrenia. It helps in reversing the low levels of dopamine and serotonin, thereby improving the patient's condition.

Technavio’s analysts forecast the global schizophrenia therapeutics market to grow at a CAGR of 1.84% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the global schizophrenia therapeutics market for 2017-2021. To calculate the market size, the report considers the sales of branded, generic, and off-label drugs.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio's report, Global Schizophrenia Therapeutics Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
• AstraZeneca
• Eli Lilly
• GlaxoSmithKline
• Johnson & Johnson
Other prominent vendors
• Alkermes
• Bristol-Myers Squibb
Market driver
• Increasing expenditure on prescription drugs
• For a full, detailed list, view our report

Market challenge
• Technological advances in non-invasive neuromodulation devices
• For a full, detailed list, view our report

Market trend
• Increase in use of LAI antipsychotic drugs
• For a full, detailed list, view our report

Key questions answered in this report
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.



Table of Contents
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
• Market outline
PART 05: Schizophrenia: Disease overview
• Schizophrenia
• Medical intervention for treating schizophrenia
• Non-medical interventions for treating schizophrenia
PART 06: Key clinical trials
PART 07: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis
PART 08: Market segmentation based on drug-class
• First-generation antipsychotic drugs
• Second-generation antipsychotic drugs
• Third generation antipsychotic drugs
PART 09: Geographical segmentation
• Market overview based on geography
• Schizophrenia therapeutics market in Americas
• Schizophrenia therapeutics market in EMEA
• Schizophrenia therapeutics market in APAC
PART 10: Decision framework
PART 11: Drivers and challenges
• Market drivers
• Market challenges
PART 12: Market trends
• Rising public interest toward mental health
• Increase in use of LAI antipsychotic drugs
• Availability of drugs with novel mechanism of action (MoA)
PART 13: Vendor landscape
• Competitive landscape
PART 14: Key vendor analysis
• AstraZeneca
• Eli Lilly
• GlaxoSmithKline
• Johnson & Johnson
• Other prominent vendors
PART 15: Appendix
• List of abbreviations
List of Exhibits
Exhibit 01: Parts of brain affected by schizophrenia
Exhibit 02: Prevalence rate of disease
Exhibit 03: Reduction in prescription revenue over the years for antipsychotic drugs due to entry of generics
Exhibit 04: Types of antipsychotic drugs
Exhibit 05: Use of antipsychotic in schizophrenia
Exhibit 06: Symptoms of disease
Exhibit 07: Non-medical treatment interventions
Exhibit 08: Pipeline landscape based on number of molecules
Exhibit 09: Key clinical trials in global schizophrenia therapeutics market 2016
Exhibit 10: Snapshot of pipeline trends in global schizophrenia therapeutics market
Exhibit 11: Global schizophrenia therapeutics market snapshot
Exhibit 12: Global schizophrenia therapeutics market 2016-2021 ($ millions)
Exhibit 13: Global schizophrenia therapeutics market: Opportunity analysis
Exhibit 14: Five forces analysis
Exhibit 15: Market segmentation of global schizophrenia therapeutics market by drug-class
Exhibit 16: Global schizophrenia therapeutics market segmentation by drug-class
Exhibit 17: Global schizophrenia market revenue by drug-class, 2016-2021 (in $ millions)
Exhibit 18: Global schizophrenia first-generation antipsychotic drugs market 2016-2021 ($ millions)
Exhibit 19: Global schizophrenia second-generation antipsychotic drugs market 2016-2021 ($ millions)
Exhibit 20: Global schizophrenia third-generation antipsychotic drugs market revenue 2016-2021 ($ millions)
Exhibit 21: Global schizophrenia therapeutics market share by geography, 2016 and 2021
Exhibit 22: Global schizophrenia therapeutics market revenue by geography, 2016-2021 ($ millions)
Exhibit 23: Global schizophrenia therapeutics market share by geography, 2016-2021
Exhibit 24: Market scenario in Americas
Exhibit 25: Schizophrenia therapeutics market in Americas 2016-2021 ($ millions)
Exhibit 26: Market scenario in EMEA
Exhibit 27: Schizophrenia therapeutics market in EMEA 2016-2021 ($ millions)
Exhibit 28: Market scenario in APAC
Exhibit 29: Schizophrenia therapeutics market in APAC 2016-2021 ($ millions)
Exhibit 30: Psychotic symptoms
Exhibit 31: Competitive structure analysis of global schizophrenia drugs market 2016
Exhibit 32: AstraZeneca: Strength assessment
Exhibit 33: AstraZeneca: Strategy assessment
Exhibit 34: AstraZeneca: Opportunity assessment
Exhibit 35: AstraZeneca: Revenue garnered by SEROQUEL XR and SEROQUEL IR 2014-2015 ($ millions)
Exhibit 36: Eli Lilly: Key highlights
Exhibit 37: Eli Lilly: Strength assessment
Exhibit 38: Eli Lilly: Strategy assessment
Exhibit 39: Eli Lilly: Opportunity assessment
Exhibit 40: GlaxoSmithKline: Key highlights
Exhibit 41: GlaxoSmithKline: Strength assessment
Exhibit 42: GlaxoSmithKline: Strategy assessment
Exhibit 43: GlaxoSmithKline: Opportunity assessment
Exhibit 44: Johnson & Johnson: Key highlights
Exhibit 45: Johnson & Johnson: Strength assessment
Exhibit 46: Johnson & Johnson: Strategy assessment
Exhibit 47: Johnson & Johnson: Opportunity assessment

PURCHASE OPTIONS
 
 
 

How can we help you?

Contact us at the Consulting WP office nearest to you or submit a business inquiry online.


  Contact
 

Subscribe to Our Newsletter

 
 
REQUEST SAMPLE    ASK FOR DISCOUNT